{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:48:02Z","timestamp":1777992482706,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.drudis.2025.104350","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:25:37Z","timestamp":1743877537000},"page":"104350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The connection between Bayesian networks and adverse outcome pathway (AOP) networks and how to use it for predicting drug toxicity"],"prefix":"10.1016","volume":"30","author":[{"given":"Dong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weida","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104350_b0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/10937404.2010.483935","article-title":"Computational toxicology as implemented by the US EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk","volume":"13","author":"Kavlock","year":"2010","journal-title":"J Toxicol Env Health, Part B"},{"key":"10.1016\/j.drudis.2025.104350_b0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1289\/ehp.1205784","article-title":"Improving the human hazard characterization of chemicals: a Tox21 update","volume":"121","author":"Tice","year":"2013","journal-title":"Environ Health Persp"},{"key":"10.1016\/j.drudis.2025.104350_b0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1289\/ehp.0901157","article-title":"Registration, evaluation, and authorization of chemicals (REACH) is but the first step\u2013how far will it take us? Six further steps to improve the European chemicals legislation","volume":"118","author":"Rud\u00e9n","year":"2010","journal-title":"Environ Health Persp"},{"key":"10.1016\/j.drudis.2025.104350_b0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1504\/IJRAM.2017.082566","article-title":"Implementing toxicity testing in the 21st century: challenges and opportunities","volume":"20","author":"Locke","year":"2017","journal-title":"Int J Risk Assess Manage"},{"key":"10.1016\/j.drudis.2025.104350_b0025","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1126\/science.1154619","article-title":"Transforming environmental health protection","volume":"319","author":"Collins","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104350_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bcpt.12239","article-title":"In vitro and modelling approaches to risk assessment from the US Environmental Protection Agency ToxCast programme","volume":"115","author":"Judson","year":"2014","journal-title":"Basic Clin Pharmacol"},{"key":"10.1016\/j.drudis.2025.104350_b0035","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acs.chemrestox.6b00135","article-title":"ToxCast chemical landscape: paving the road to 21st century toxicology","volume":"29","author":"Richard","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0040","doi-asserted-by":"crossref","first-page":"D921","DOI":"10.1093\/nar\/gku955","article-title":"Open TG-GATEs: a large-scale toxicogenomics database","volume":"43","author":"Igarashi","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2025.104350_b0045","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104350_b0050","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/tx500501h","article-title":"Predicting hepatotoxicity using ToxCast in vitro bioactivity and chemical structure","volume":"28","author":"Liu","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0055","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1038\/ncomms10425","article-title":"Modelling the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization","volume":"7","author":"Huang","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104350_b0060","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1021\/acs.chemrestox.6b00347","article-title":"Development and validation of a computational model for androgen receptor activity","volume":"30","author":"Kleinstreuer","year":"2017","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/etc.34","article-title":"Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment","volume":"29","author":"Ankley","year":"2010","journal-title":"Environ Toxicol Chem"},{"key":"10.1016\/j.drudis.2025.104350_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10937404.2010.483176","article-title":"Toxicity testing in the 21st century: a vision and a strategy","volume":"13","author":"Krewski","year":"2010","journal-title":"J Toxicol Env Health, Part B"},{"key":"10.1016\/j.drudis.2025.104350_b0075","series-title":"Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference","author":"Pearl","year":"1988"},{"key":"10.1016\/j.drudis.2025.104350_b0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/risa.13423","article-title":"Predicting the probability that a chemical causes steatosis using adverse outcome pathway Bayesian networks (AOPBNs)","volume":"40","author":"Burgoon","year":"2020","journal-title":"Risk Anal"},{"issue":"3","key":"10.1016\/j.drudis.2025.104350_b0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ieam.1708","article-title":"Limitations of toxicity characterization in life cycle assessment: can adverse outcome pathways provide a new foundation?","volume":"12","author":"Gust","year":"2015","journal-title":"Integr Environ Assess Manag"},{"key":"10.1016\/j.drudis.2025.104350_b0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/17435390.2022.2140615","article-title":"Quantitative adverse outcome pathway (qAOP) using bayesian network model on comparative toxicity of multi-walled carbon nanotubes (MWCNTs): safe-by-design approach","volume":"16","author":"Jeong","year":"2022","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.drudis.2025.104350_b0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ieam.4871","article-title":"Evaluating the effects of climate change and chemical, physical, and biological stressors on nearshore coral reefs: a case study in the Great Barrier Reef","volume":"20","author":"Mentzel","year":"2024","journal-title":"Australia Integr Environ Assess Manag"},{"key":"10.1016\/j.drudis.2025.104350_b0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ieam.4369","article-title":"Increased use of Bayesian network models has improved environmental risk assessments","volume":"17","author":"Moe","year":"2020","journal-title":"Integr Environ Assess Manag"},{"key":"10.1016\/j.drudis.2025.104350_b0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ieam.4348","article-title":"Quantification of an adverse outcome pathway network by Bayesian regression and Bayesian network modeling","volume":"17","author":"Moe","year":"2020","journal-title":"Integr Environ Assess Manag"},{"key":"10.1016\/j.drudis.2025.104350_b0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.14573\/altex.1310151","article-title":"Open source software implementation of an integrated testing strategy for skin sensitization potency based on a Bayesian network","volume":"31","author":"Pirone","year":"2014","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2025.104350_b0115","unstructured":"AOP: Aryl hydrocarbon receptor activation leading to uroporphyria. AOPwiki website. https:\/\/aopwiki.org\/aops\/131 [Accessed March 30, 2025]."},{"key":"10.1016\/j.drudis.2025.104350_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tox.2013.08.011","article-title":"The adverse outcome pathway concept: a pragmatic tool in toxicology","volume":"312","author":"Vinken","year":"2013","journal-title":"Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cotox.2018.03.004","article-title":"The adverse outcome pathway: a multifaceted framework supporting 21st century toxicology","volume":"9","author":"Ankley","year":"2018","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0130","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/ijms22020933","article-title":"Endocrine disrupting chemicals: current understanding, new testing strategies and future research needs","volume":"22","author":"Street","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104350_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114650","article-title":"Application of AOPs to assist regulatory assessment of chemical risks\u2013case studies, needs and recommendations","volume":"217","author":"Bajard","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.drudis.2025.104350_b0140","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1210\/er.2015-1010","article-title":"EDC-2: The Endocrine Society\u2019s second scientific statement on endocrine-disrupting chemicals","volume":"36","author":"Gore","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.drudis.2025.104350_b0145","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41574-023-00872-x","article-title":"The regulation of endocrine-disrupting chemicals to minimize their impact on health","volume":"19","author":"Duh-Leong","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.drudis.2025.104350_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2024.1357717","article-title":"Building an adverse outcome pathway network for estrogen-, androgen-and steroidogenesis-mediated reproductive toxicity","volume":"6","author":"Zilliacus","year":"2024","journal-title":"Front Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115370","article-title":"Generating adverse outcome pathway (AOP) of inorganic arsenic-induced adult male reproductive impairment via integration of phenotypic analysis in comparative toxicogenomics database (CTD) and AOP wiki","volume":"411","author":"Chai","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2025.104350_b0160","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00204-019-02551-1","article-title":"Development and analysis of an adverse outcome pathway network for human neurotoxicity","volume":"93","author":"Spinu","year":"2019","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0165","article-title":"AOP-networkFinder\u2014a versatile tool for the reconstruction and visualization of adverse outcome pathway networks from AOP-Wiki","volume":"5","author":"Yarar","year":"2025","journal-title":"Bioinform Adv"},{"key":"10.1016\/j.drudis.2025.104350_b0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.taap.2018.02.006","article-title":"AOP-DB: a database resource for the exploration of adverse outcome pathways through integrated association networks","volume":"343","author":"Pittman","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"24","key":"10.1016\/j.drudis.2025.104350_b0175","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1093\/bioinformatics\/btz570","article-title":"sAOP: linking chemical stressors to adverse outcomes pathway networks","volume":"35","author":"Aguayo-Orozco","year":"2019","journal-title":"Bioinform"},{"key":"10.1016\/j.drudis.2025.104350_b0180","series-title":"Learning Bayesian Networks","author":"Neapolitan","year":"2004"},{"key":"10.1016\/j.drudis.2025.104350_b0185","series-title":"Bayesian Networks in R","author":"Nagarajan","year":"2013"},{"key":"10.1016\/j.drudis.2025.104350_b0190","series-title":"Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003)","article-title":"JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling","author":"Plummer","year":"2003"},{"key":"10.1016\/j.drudis.2025.104350_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.drudis.2025.104350_b0200","series-title":"Bayesian Networks and BayesiaLab: A Practical Introduction for Researchers","author":"Conrady","year":"2015"},{"key":"10.1016\/j.drudis.2025.104350_b0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2013.16","article-title":"The liver toxicity knowledge base: a systems approach to a complex end point","volume":"93","author":"Chen","year":"2013","journal-title":"Clin Pharm Therap"},{"key":"10.1016\/j.drudis.2025.104350_b0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17474124.2018.1383154","article-title":"The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury","volume":"12","author":"Thakkar","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104350_b0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/aivt.2017.0027","article-title":"An update on adverse outcome pathways leading to liver injury","volume":"3","author":"Gijbels","year":"2017","journal-title":"Appl Vitro Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0220","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/acs.chemrestox.8b00112","article-title":"Adverse outcome pathway-driven analysis of liver steatosis in vitro: a case study with cyproconazole","volume":"31","author":"Luckert","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14740338.2024.2326479","article-title":"Chemical-induced liver cancer: an adverse outcome pathway perspective","volume":"23","author":"Sanz-Serrano","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2025.104350_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2020.115733","article-title":"A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study","volume":"268","author":"Jin","year":"2021","journal-title":"Environ Pollut"},{"key":"10.1016\/j.drudis.2025.104350_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.152856","article-title":"Derivation, characterisation and analysis of an adverse outcome pathway network for human hepatotoxicity","volume":"459","author":"Arnesdotter","year":"2021","journal-title":"Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0240","article-title":"Adverse outcome pathway networks as the basis for the development of new approach methodologies: liver toxicity as a case study","volume":"40","author":"Vinken","year":"2024","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10408444.2015.1089471","article-title":"The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways","volume":"46","author":"Mellor","year":"2016","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0250","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00204-016-1814-8","article-title":"Adverse outcome pathway development from protein alkylation to liver fibrosis","volume":"91","author":"Horvat","year":"2017","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.28678","article-title":"A model to predict severity of drug-induced liver injury in humans","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.drudis.2025.104350_b0260","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/bioinformatics\/bty784","article-title":"The GCTx format and cmap {Py, R, M, J} packages: resources for optimized storage and integrated traversal of annotated dense matrices","volume":"35","author":"Enache","year":"2019","journal-title":"Bioinform"},{"key":"10.1016\/j.drudis.2025.104350_b0265","first-page":"187","article-title":"Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI)","volume":"37","author":"Khadka","year":"2020","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2025.104350_b0270","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00204-014-1276-9","article-title":"A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the \u2018rule-of-two\u2019 model","volume":"88","author":"Chen","year":"2014","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2025.104350_b0275","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1214\/13-BA805","article-title":"Asymptotic properties of Bayes risk for the horseshoe prior","volume":"8","author":"Datta","year":"2013","journal-title":"Bayesian Anal"},{"key":"10.1016\/j.drudis.2025.104350_b0280","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1214\/14-EJS962","article-title":"The horseshoe estimator: posterior concentration around nearly black vectors","volume":"8","author":"Van Der Pas","year":"2014","journal-title":"Electron J Stat"},{"key":"10.1016\/j.drudis.2025.104350_b0285","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jrsm.1597","article-title":"Bayesian sparse modeling to identify high\u2010risk subgroups in meta\u2010analysis of safety data","volume":"13","author":"Qi","year":"2022","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.drudis.2025.104350_b0290","first-page":"73","article-title":"Handling sparsity via the horseshoe","volume":"5","author":"Carvalho","year":"2009","journal-title":"Proc Machine Learn Res"},{"key":"10.1016\/j.drudis.2025.104350_b0295","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1214\/ss\/1177010894","article-title":"Comment: Graphical models, causality and intervention","volume":"8","author":"Pearl","year":"1993","journal-title":"Statist Sci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:17:25Z","timestamp":1758125845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1359644625000637"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104350","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The connection between Bayesian networks and adverse outcome pathway (AOP) networks and how to use it for predicting drug toxicity","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104350"}}